Kras G12c Mutated Non Small Cell Lung Cancer clinical trials

Explore recruiting kras g12c mutated non small cell lung cancer clinical trials.

Recruiting kras g12c mutated non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Kras G12c Mutated Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Sotorasib in advanced KRAS G12C-mutated non-small cell lung cancer patients with comorbidities (SOLUCOM)

Norway, Denmark, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

Netherlands, Hungary, Germany, Belgium, France, Spain +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments

Spain, Italy, France, Denmark, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Kras G12c Mutated Non Small Cell Lung Cancer trials by city

Kras G12c Mutated Non Small Cell Lung Cancer in Toronto Kras G12c Mutated Non Small Cell Lung Cancer in Vancouver Kras G12c Mutated Non Small Cell Lung Cancer in Montreal Kras G12c Mutated Non Small Cell Lung Cancer in Calgary Kras G12c Mutated Non Small Cell Lung Cancer in Edmonton Kras G12c Mutated Non Small Cell Lung Cancer in Ottawa Kras G12c Mutated Non Small Cell Lung Cancer in Winnipeg Kras G12c Mutated Non Small Cell Lung Cancer in Quebec City Kras G12c Mutated Non Small Cell Lung Cancer in Hamilton Kras G12c Mutated Non Small Cell Lung Cancer in Kitchener Kras G12c Mutated Non Small Cell Lung Cancer in London Kras G12c Mutated Non Small Cell Lung Cancer in Halifax Kras G12c Mutated Non Small Cell Lung Cancer in New York Kras G12c Mutated Non Small Cell Lung Cancer in Los Angeles Kras G12c Mutated Non Small Cell Lung Cancer in Chicago Kras G12c Mutated Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease